Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-100 in Advanced Solid Tumors
NCT03050047Phase 1Unknown
- Sponsor
- BIOCAD
- Start
- Aug 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of prolgolimab in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 3 more (4 arms), sponsored by BIOCAD. Primary endpoint: Objective Response Rate at 85 days. Status: unknown.
02
Drugs
prolgolimab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)pleural mesotheliomabladder cancer
Beyond the preview
Go deeper on NCT03050047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050047.